The FDA has approved the first clinical trial for transplanting genetically modified pig kidneys into humans, a significant milestone in medical research. Set to launch in summer 2025, the trial at NYU Langone Health will start with six participants, potentially expanding to 50. This initiative aims to provide a solution for the critical organ shortage faced by over 103,000 patients in the U.S. The trial represents a promising avenue for improving transplant outcomes, particularly for those ineligible for human kidneys.
The FDA's approval marks a significant step forward in addressing the organ transplant shortage, potentially offering hope to thousands waiting for kidney transplants.
This groundbreaking trial, set to start this summer, signifies a vital opportunity to assess the safety and effectiveness of genetically modified pig kidneys for human transplantation.
Collection
[
|
...
]